Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04110093 |
TitleRegorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer | Phase
Phase 1/Phase 2
|
Date Added 2019-10-01 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Regorafenib and PD-1 inhibitor |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04104776 |
TitleA Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | Phase
Phase 1
|
Date Added 2019-09-26 |
Location
Georgia, United States
Illinois, United States Maryland, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Texas, United States Virginia, United States Washington, United States France Italy Korea, Republic of Poland Spain United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
CPI-0209, CPI-0209 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04096417 |
TitlePemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations | Phase
Phase 2
|
Date Added 2019-09-19 |
Location
Arizona, United States
Georgia, United States Minnesota, United States North Carolina, United States Tennessee, United States Wisconsin, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Pemigatinib |
Tags
MSS/ MMRp
|
| NCT ID NCT04092673 |
TitleStudy of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies | Phase
Phase 1
|
Date Added 2019-09-17 |
Location
California, United States
Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
eFT226, eFT226 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04085185 |
TitleA Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors | Phase
Phase 1
|
Date Added 2019-09-11 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
IBI110, IBI110+ Sintilimab, IBI110, Sintilinab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04062721 |
TitleLocal Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases | Phase
Phase 1
|
Date Added 2019-08-20 |
Location
France
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
Chemotherapy, In situ immunotherapy |
Tags
MSS/ MMRp
|
| NCT ID NCT04050709 |
TitleQUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers | Phase
Phase 1
|
Date Added 2019-08-08 |
Location
California, United States
|
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
PD-L1 t-haNK |
Tags
MSS/ MMRp
|
| NCT ID NCT04046445 |
TitlePhase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer | Phase
Phase 1
|
Date Added 2019-08-06 |
Location
Arizona, United States
California, United States Colorado, United States New York, United States North Carolina, United States Texas, United States Belgium Germany Switzerland |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
ATP128, BI 754091, VSV-GP128 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04041310 |
TitleNous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2019-08-01 |
Location
California, United States
Florida, United States Indiana, United States Maryland, United States Missouri, United States New York, United States Texas, United States Belgium Canada Italy Spain United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs |
Tags
MSI-H/ MMRd
|
| NCT ID NCT04017650 |
TitleEncorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2019-07-12 |
Location
Texas, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
cetuximab, encorafenib, Nivolumab |
Tags
MSS/ MMRp
|




